Keyphrases
Israel
100%
COVID-19
78%
Streptococcus Pneumoniae
49%
Healthcare Workers
41%
BNT162b2 Vaccine
37%
Staphylococcus Aureus
34%
Neutralizing Antibodies
34%
BNT162b2
32%
Invasive Pneumococcal Disease
31%
PCV7
30%
Immunogenicity
29%
13-valent Pneumococcal Conjugate Vaccine (PCV13)
24%
Pneumococcal Conjugate Vaccine
21%
Vaccination
21%
Vaccine Dose
20%
COVID-19 Vaccine
19%
S. Pneumoniae
19%
COVID-19 Vaccination
19%
Medical Center
17%
Breakthrough Infection
16%
Third Dose
16%
Confidence Interval
15%
Immune Response
15%
Prospective Cohort Study
15%
SHEBA
15%
IgG Antibody
14%
BA.1
14%
Second Dose
14%
CA-MRSA
14%
Staphylococcus Aureus Carriage
14%
BA.5
13%
Omicron Variant
13%
Pregnant Women
12%
Israeli
12%
Nationwide Surveillance
12%
S. Aureus Carriage
12%
Methicillin-resistant Staphylococcus Aureus
10%
Receptor-binding Domain
10%
IgG Levels
10%
Surveillance Studies
10%
Risk Factors
10%
Two-dose
10%
Odds Ratio
10%
Unvaccinated
9%
Pili
9%
Vaccine Types
9%
Revaccination
8%
Pneumococcal Serotypes
8%
Co-colonization
8%
Vaccination in Pregnancy
8%
Immunology and Microbiology
Vaccine Efficacy
84%
Vaccination Policy
58%
COVID-19
48%
Streptococcus Pneumoniae
48%
Serotype
46%
Severe Acute Respiratory Syndrome Coronavirus 2
43%
Staphylococcus Aureus
41%
Neutralizing Antibody
30%
Omicron Coronavirus Variant
26%
Pneumococcal Vaccine
25%
Methicillin-Resistant Staphylococcus Aureus
23%
Pneumococcus
19%
Prevalence
19%
Immune Response
18%
Immunoglobulin G Antibody
17%
Antibody Titer
16%
Breakthrough Infection
15%
Immunogenicity
12%
Humoral Immunity
11%
Neutralization
11%
Penicillin
10%
Pilus
10%
Comorbidity
10%
Receptor Binding
10%
Dynamics
9%
Polymerase Chain Reaction
9%
Antibody Response
8%
Wild Type
7%
Coronavirinae
7%
Hydrogen Peroxide
6%
Monospecific Antibody
6%
Antimicrobial Resistance
6%
Upper Respiratory Tract
6%
Immunoglobulin G
6%
Infectious Agent
5%
Spike
5%
Carbapenemase Producing Enterobacteriaceae
5%
Transplant Procedure
5%
Seropositivity
5%
Titer
5%
Severe Acute Respiratory Syndrome
5%
Medicine and Dentistry
Severe Acute Respiratory Syndrome Coronavirus 2
55%
COVID-19
52%
Infection
52%
Pneumococcal Infection
26%
Streptococcus Pneumoniae
21%
Disease
21%
Serotype
20%
Immunoglobulin G Antibody
18%
Antibiotics
16%
Health Care
15%
Neutralizing Antibody
14%
Staphylococcus Aureus
14%
Prospective Cohort Study
12%
Pneumococcus Vaccine
12%
Antibody Response
10%
Coronavirinae
10%
Immune Response
10%
Receptor Binding
10%
Emergency Department
9%
COVID-19 Vaccine
9%
Adverse Event
8%
Household
8%
Neutralization
8%
Humoral Immunity
8%
Observational Study
8%
Pneumococcus
8%
Immunoglobulin G
7%
Immunoglobulin A
7%
Obstetrics
6%
Triage
6%
Primary Health Care
6%
COVID-19 Vaccination
6%
Neonatal Infant
6%
Methicillin Resistant Staphylococcus Aureus
5%
Severe Acute Respiratory Syndrome
5%
Antibiotic Therapy
5%
Antibiotic Resistance
5%
Penicillin Derivative
5%